Jrg Ellinger

List of Publications by Year in Descending Order

158 papers	5,253 citations	42 h-index	66 g-index
188 ext. papers	6,075 ext. citations	4.1 avg, IF	5.33 L-index

#	Paper	IF	Citations
158	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper.. *Cancers*, **2022**, 14,	6.6	2
157	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.. *Urologia Internationalis*, **2022**, 1-8	1.9	0
156	MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors.. *Journal of Cancer Research and Clinical Oncology*, **2022**, 1	4.9	1
155	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.. *European Journal of Cancer*, **2022**, 167, 13-22	7.5	0
154	C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.. *Clinical and Translational Immunology*, **2021**, 10, e1358	6.8	1
153	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. *European Urology Focus*, **2021**, 7, 1121-1129	5.1	1
152	N -Methyladenosine (m A) readers are dysregulated in renal cell carcinoma. *Molecular Carcinogenesis*, **2021**, 60, 354-362	5	2
151	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. *American Journal of Pathology*, **2021**, 191, 618-630	5.8	1
150	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. *Cancers*, **2021**, 13,	6.6	7
149	Systematic expression analysis of mA RNA methyltransferases in clear cell renal cell carcinoma.. *BJUI Compass*, **2021**, 2, 402-411	0.9	1
148	Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. *Journal of Nuclear Medicine*, **2021**,	8.9	3
147	Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?. *Anticancer Research*, **2021**, 41, 3037-3043	2.3	1
146	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. *International Journal of Urology*, **2021**, 28, 424-431	2.3	0
145	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. *Apmis*, **2021**, 129, 204-212	3.4	3
144	promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma **2021**, 9,		2
143	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. *Clinical Genitourinary Cancer*, **2021**,	3.3	3
142	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. *Translational Oncology*, **2020**, 13, 100844	4.9	2

141	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 687.e1-687.e11	2.8	2
140	Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2255-2265	4.9	4
139	The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. *Clinical and Translational Oncology*, **2020**, 22, 1524-1531	3.6	7
138	The N -methyladenosine (m A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. *BJU International*, **2020**, 125, 617-624	5.6	31
137	(,) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma **2020**, 8,		28
136	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. *Journal of Clinical Oncology*, **2020**, 38, e17592-e17592	2.2	1
135	DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype. *Current Genomics*, **2020**, 21, 34-36	2.6	10
134	and DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
133	Low Plasma Appearance of (+)-Catechin and (-)-Catechin Compared with Epicatechin after Consumption of Beverages Prepared from Nonalkalized or Alkalized Cocoa-A Randomized, Double-Blind Trial. *Nutrients*, **2020**, 12,	6.7	5
132	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. *Frontiers in Oncology*, **2020**, 10, 1775	5.3	10
131	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. *Translational Andrology and Urology*, **2020**, 9, 1314-1322	2.3	7
130	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. *Cancers*, **2020**, 12,	6.6	1
129	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. *Scientific Reports*, **2020**, 10, 18857	4.9	2
128	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. *Cancers*, **2020**, 12,	6.6	5
127	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. *Cancer Genetics*, **2019**, 235-236, 18-20	2.3	7
126	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifies COX5B as a prognostic marker in clear cell renal cell carcinoma. *International Journal of Urology*, **2019**, 26, 910-916	2.3	4
125	Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. *In Vivo*, **2019**, 33, 1935-1940	2.3	1
124	Apelin and apelin receptor expression in renal cell carcinoma. *British Journal of Cancer*, **2019**, 120, 633-639	5.7	14

123	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. *World Journal of Urology*, **2019**, 37, 1639-1647	4	13
122	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, e167-e175	3.3	7
121	Cell-Free DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. *Clinical Chemistry*, **2019**, 65, 559-568	5.5	9
120	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. *World Journal of Urology*, **2018**, 36, 1073-1078	4	12
119	The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. *Annals of Diagnostic Pathology*, **2018**, 34, 18-26	2.2	3
118	Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report. *BMC Urology*, **2018**, 18, 21	2.2	2
117	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. *Urologia Internationalis*, **2018**, 101, 16-24	1.9	23
116	The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma. *Cancer Biomarkers*, **2018**, 21, 839-847	3.8	5
115	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. *European Urology Focus*, **2018**, 4, 260-266	5.1	17
114	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. *Journal of Urology*, **2018**, 199, 370-377	2.5	40
113	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. *Clinical Epigenetics*, **2018**, 10, 11	7.7	46
112	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cellsQ malignancy. *Oncology Letters*, **2018**, 16, 3013-3021	2.6	3
111	5QtRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. *Journal of Urology*, **2018**, 199, 378-383	2.5	30
110	tRNA-halves are prognostic biomarkers for patients with prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 503.e1-503.e7	2.8	20
109	ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. *Scientific Reports*, **2017**, 7, 42170	4.9	16
108	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. *Clinical Chemistry*, **2017**, 63, 1288-1296	5.5	60
107	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. *Clinical Genitourinary Cancer*, **2017**, 15, e809-e817	3.3	17
106	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. *Journal of Molecular Diagnostics*, **2017**, 19, 107-114	5.1	30

105	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. *Clinical Genitourinary Cancer*, **2017**, 15, e551-e562	3.3	8
104	YRNA expression predicts survival in bladder cancer patients. *BMC Cancer*, **2017**, 17, 749	4.8	15
103	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. *Pathology*, **2017**, 49, 665-668	1.6	1
102	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. *Translational Oncology*, **2017**, 10, 661-668	4.9	27
101	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. *Frontiers in Medicine*, **2017**, 4, 30	4.9	8
100	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. *Oncotarget*, **2017**, 8, 75076-75086	3.3	6
99	The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. *Anticancer Research*, **2017**, 37, 6685-6695	2.3	3
98	The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. *Expert Review of Molecular Diagnostics*, **2016**, 16, 1059-1065	3.8	14
97	promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. *Clinical Epigenetics*, **2016**, 8, 104	7.7	8
96	Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report. *Urologia Internationalis*, **2016**, 97, 369-372	1.9	
95	Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. *Urologia Internationalis*, **2016**, 96, 39-45	1.9	3
94	Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. *Molecular Cancer*, **2016**, 15, 10	42.1	43
93	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 1969-77	12.9	128
92	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 86490-86499	3.3	18
91	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. *Oncotarget*, **2016**, 7, 23043-55	3.3	20
90	CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. *Oncotarget*, **2016**, 7, 53309-53320	3.3	31
89	PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. *Oncotarget*, **2016**, 7, 79943-79955	3.3	62
88	Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. *Scientific Reports*, **2016**, 6, 37158	4.9	47

87	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 1599-607	4.9	30
86	Seminoma Clinical Stage 1 - Patterns of Care in Germany. *Urologia Internationalis*, **2016**, 96, 390-8	1.9	10
85	Promoter methylation of the immune checkpoint receptor () is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. *OncoImmunology*, **2016**, 5, e1221555	7.2	37
84	CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. *Epigenetics*, **2016**, 11, 871-880	5.7	29
83	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. *Anticancer Research*, **2016**, 36, 3961-4	2.3	15
82	Epigenetic biomarkers in the blood of patients with urological malignancies. *Expert Review of Molecular Diagnostics*, **2015**, 15, 505-16	3.8	45
81	Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. *Genomics Data*, **2015**, 5, 173-5		27
80	Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. *Clinical Epigenetics*, **2015**, 7, 10	7.7	67
79	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. *World Journal of Urology*, **2015**, 33, 1945-50	4	16
78	Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. *Journal of Urology*, **2015**, 193, 331-7	2.5	118
77	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. *Diagnostic Pathology*, **2015**, 10, 165	3	8
76	Evidence from the QROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)Q study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?. *Annals of Surgical Oncology*, **2015**, 22, 1032-42	3.1	26
75	Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. *PLoS ONE*, **2015**, 10, e0117284	3.7	31
74	The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. *American Journal of Cancer Research*, **2015**, 5, 2799-807	4.4	31
73	NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. *American Journal of Cancer Research*, **2015**, 5, 2816-22	4.4	8
72	Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer. *Urologia Internationalis*, **2014**, 93, 113-8	1.9	24
71	Nucleic acid-based tissue biomarkers of urologic malignancies. *Critical Reviews in Clinical Laboratory Sciences*, **2014**, 51, 173-99	9.4	28
70	KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. *American Journal of Pathology*, **2014**, 184, 2430-7	5.8	48

69	Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. *World Journal of Urology*, **2014**, 32, 353-8	4	95
68	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). *BJU International*, **2014**, 113, 209-17	5.6	16
67	Diagnostic meaning of urodynamic studies in pouch incontinence: results of a small series. *Urologia Internationalis*, **2014**, 92, 237-41	1.9	2
66	Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. *World Journal of Urology*, **2014**, 32, 365-71	4	3
65	Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. *American Journal of Cancer Research*, **2014**, 4, 952-62	4.4	9
64	MicroRNAs: a novel non-invasive biomarker for patients with urological malignancies. *Current Pharmaceutical Biotechnology*, **2014**, 15, 486-91	2.6	7
63	Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. *Anticancer Research*, **2014**, 34, 665-9	2.3	36
62	Epigenetic regulation of microRNA expression in renal cell carcinoma. *Biochemical and Biophysical Research Communications*, **2013**, 436, 79-84	3.4	15
61	Spindle cell rhabdomyosarcoma of the prostate. *International Journal of Urology*, **2013**, 20, 935-7	2.3	6
60	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. *European Journal of Surgical Oncology*, **2013**, 39, 372-9	3.6	11
59	Histone methylation defines an epigenetic entity in penile squamous cell carcinoma. *Journal of Urology*, **2013**, 189, 1117-22	2.5	7
58	Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1141-7	2.8	45
57	Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. *Anticancer Research*, **2013**, 33, 779-84	2.3	22
56	Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. *Anticancer Research*, **2013**, 33, 4651-6	2.3	39
55	Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. *International Journal of Urology*, **2012**, 19, 1017-25	2.3	75
54	Alterations of global histone H4K20 methylation during prostate carcinogenesis. *BMC Urology*, **2012**, 12, 5	2.2	41
53	Bolus consumption of a specifically designed fruit juice rich in anthocyanins and ascorbic acid did not influence markers of antioxidative defense in healthy humans. *Journal of Agricultural and Food Chemistry*, **2012**, 60, 11292-300	5.7	15
52	Tyrosine kinase expression profile in clear cell renal cell carcinoma. *World Journal of Urology*, **2012**, 30, 559-65	4	31

51	External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. *Journal of Urology*, **2012**, 187, 1210-4	2.5	7
50	Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 509-15	2.8	73
49	Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. *Cancer Investigation*, **2012**, 30, 92-7	2.1	44
48	Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. *Biochemical and Biophysical Research Communications*, **2012**, 417, 29-34	3.4	9
47	External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *European Journal of Surgical Oncology*, **2012**, 38, 637-42	3.6	9
46	Kinetics of L-theanine uptake and metabolism in healthy participants are comparable after ingestion of L-theanine via capsules and green tea. *Journal of Nutrition*, **2012**, 142, 2091-6	4.1	36
45	Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. *Cancer Epidemiology*, **2012**, 36, 391-4	2.8	87
44	Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. *Gender Medicine*, **2012**, 9, 481-9		58
43	Identification of prostaglandin receptors in human ureters. *BMC Urology*, **2012**, 12, 35	2.2	4
42	Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. *BJU International*, **2012**, 109, 459-65	5.6	53
41	Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable?. *Clinical Genitourinary Cancer*, **2012**, 10, 32-6	3.3	4
40	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?. *Molecular Medicine Reports*, **2012**, 5, 313-6	2.9	34
39	Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors. *Molecular Medicine Reports*, **2012**, 5, 32-6	2.9	4
38	Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. *Urologia Internationalis*, **2012**, 88, 390-4	1.9	29
37	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. *Chest*, **2012**, 142, 1020-1026	5.3	43
36	Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. *Anticancer Research*, **2012**, 32, 879-86	2.3	21
35	Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-)in advanced prostate cancer. *Anticancer Research*, **2012**, 32, 3479-83	2.3	26
34	Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. *Biochemical and Biophysical Research Communications*, **2011**, 412, 606-11	3.4	11

33	Circulating microRNAs (miRNA) in serum of patients with prostate cancer. *Urology*, **2011**, 77, 1265.e9-16	1.6	192
32	Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. *BJU International*, **2011**, 108, E290-6	5.6	54
31	The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2011**, 29, 124-9	2.8	42
30	Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. *International Journal of Molecular Medicine*, **2011**, 28, 799-807	4.4	5
29	DNA hypermethylation in papillary renal cell carcinoma. *BJU International*, **2011**, 107, 664-9	5.6	21
28	Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. *BJU International*, **2011**, 108, E278-83	5.6	10
27	Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. *European Urology*, **2011**, 59, 712-8	10.2	60
26	Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. *Annals of Surgical Oncology*, **2011**, 18, 2018-25	3.1	85
25	Comparison of myocardial remodeling between cryoinfarction and reperfused infarction in mice. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 961298		15
24	Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. *Scandinavian Journal of Urology and Nephrology*, **2011**, 45, 251-7		12
23	MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. *PLoS ONE*, **2011**, 6, e25787	3.7	187
22	Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. *Cancer Science*, **2010**, 101, 2664-9	6.9	80
21	H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. *Human Pathology*, **2010**, 41, 181-9	3.7	79
20	Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. *International Journal of Cancer*, **2010**, 127, 2360-6	7.5	87
19	Global levels of histone modifications predict prostate cancer recurrence. *Prostate*, **2010**, 70, 61-9	4.2	172
18	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. *BJU International*, **2009**, 104, 48-52	5.6	65
17	Saturation biopsy improves preoperative Gleason scoring of prostate cancer. *Pathology Research and Practice*, **2009**, 205, 259-64	3.4	10
16	Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. *Journal of Urology*, **2009**, 181, 363-71	2.5	63

15	CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. *Journal of Urology*, **2009**, 182, 324-9	2.5	69
14	First report of an unexpected blind-ending duplication of the ureter as a rare pitfall in kidney transplantation. *Transplant International*, **2008**, 21, 696-7	3	
13	Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. *BJU International*, **2008**, 102, 628-32	5.6	63
12	Soy isoflavone genistein in prevention and treatment of prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2008**, 11, 6-12	6.2	93
11	Stem cell marker expression in small cell lung carcinoma and developing lung tissue. *Human Pathology*, **2008**, 39, 1597-605	3.7	41
10	CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. *Urology*, **2008**, 71, 161-7	1.6	103
9	Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. *Cancer Letters*, **2008**, 264, 274-80	9.9	51
8	Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. *Journal of Urology*, **2008**, 179, 346-52	2.5	58
7	CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. *Prostate*, **2008**, 68, 42-9	4.2	100
6	Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. *International Journal of Cancer*, **2008**, 122, 138-43	7.5	72
5	Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. *European Urology*, **2007**, 51, 665-74; discussion 674	10.2	62
4	Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. *Cancer Research*, **2006**, 66, 11341-7	10.1	384
3	Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. *Urology*, **2006**, 68, 257-62	1.6	82
2	Tomatoes, tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies?. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2006**, 9, 722-7	3.8	40
1	Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. *Clinical Cancer Research*, **2005**, 11, 4097-106	12.9	121